Early Hemlibra use prevents bleeding in babies with hem A
Starting Hemlibra (emicizumab) early is safe and helps to prevent bleeding in babies with severe hemophilia A who…
Articles by Margarida Maia, PhD
Delaying immune drugs with Hemlibra boosts survival: Study
Delaying the start of immunosuppressive treatment in adults diagnosed with acquired hemophilia A who are receiving Hemlibra (emicizumab-kxwh)…
Adynovate controls bleeding in real world for hemophilia A patients
In a real-world study in South Korea, preventive treatment with Adynovate (rurioctocog alfa pegol) was shown to be effective…
Roctavian sustains bleed control, maintains factor VIII for 5 years
A single dose of Roctavian (valoctocogene roxaparvovec-rvox), a gene therapy for severe hemophilia A from BioMarin Pharmaceutical, maintains factor…
Extended hemophilia half-life products aid care, but raise costs
Adults with hemophilia who switched from standard to extended half-life replacement treatment needed fewer infusions, had fewer bleeds per…
More preventive treatment options needed, researchers say
Prophylactic (preventive) treatment for hemophilia AÂ and B is generally more effective than on-demand treatment in reducing the frequency…
Women, girls in focus on World Hemophilia Day
World Hemophilia Day is April 17, and this year it will focus on the challenges of women and girls living…
Takeda to discontinue Hemofil M, Recombinate for hemophilia A
Takeda Pharmaceuticals has decided to discontinue Hemofil M (human antihemophilic factor) and Recombinate (recombinant antihemophilic factor), both of…
Blood stem-cell gene therapy leads to stable FVIII levels in small study
An experimental gene therapy using modified blood stem cells helped five adults with severe hemophilia A attain therapeutic levels…
Sangamo to regain rights to hemophilia A gene therapy
Sangamo Therapeutics will regain full rights to develop and market giroctocogene fitelparvovec, a gene therapy candidate for adults…